[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507796":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":39,"responsibleParty":56,"collaborators":18,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Jilin University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention","EXPERIMENTAL","patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician. in addition the patient will receive rivaroxaban 15mg daily in addition to the dual antiplatelet therapy.",[13],"Drug: Rivaroxaban 15 MG [Xarelto]",{"label":15,"type":16,"description":17,"interventionNames":18},"control","NO_INTERVENTION","patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Rivaroxaban 15 MG [Xarelto]","Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.",[9],[26],"Xarelto",[28],{"name":29,"affiliation":30,"role":31},"Mingyou Zhang","The First Hospital of Jilin University","PRINCIPAL_INVESTIGATOR",[33,37],{"name":29,"role":34,"phone":35,"phoneExt":18,"email":36},"CONTACT","86-431-88782342","zmy@jlu.edu.cn",{"name":38,"role":34,"phone":35,"phoneExt":18,"email":18},"Zhaoxi Liu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Jilin university","RECRUITING","Changchun","Jilin","130000","China","CN",{"type":49,"coordinates":50},"Point",[51,52],125.32278,43.88,{"lat":52,"lon":51},[55],{"name":29,"role":34,"phone":18,"phoneExt":18,"email":18},{"type":31,"investigatorFullName":29,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Associate prof","100507796","anti-coagulation-on-left-ventricular-thrombus-after-st-segment-elevation-myocardial-infarction-100507796",false,"NCT05892042","Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction","ACTonLVT","Inclusion Criteria:\n\nEstablished ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE.\n\nOngoing treatment with dual anti-platelet therapy according to ESC\u002FAHA guidelines at the time of randomization\n\nExclusion Criteria:\n\nClinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT.\n\nAny contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent","ALL","18 Years","80 Years",{"count":70,"type":71},320,"ESTIMATED","INTERVENTIONAL",[74],"NA","Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction",[77,78],"ST-segment Elevation Myocardial Infarction (STEMI)","Left Ventricular Thrombus",[80],"STEMI, LVT, Anticoagulation","2026-05-27",{"date":83,"type":84},"2026-06-01","ACTUAL",{"date":86,"type":84},"2023-05-01",{"date":88,"type":71},"2026-12-01",{"name":5,"class":6},1]